The goal of this clinical trial is to learn whether a topical formulation containing 12% azelaic acid and 5% tranexamic acid is effective and safe for treating melasma in adults. The main questions it aims to answer are:
Does the topical formulation reduce melasma severity compared with placebo after 4 weeks of treatment? Is the topical formulation safe and well tolerated?
Researchers will compare the active topical formulation with a placebo cream to determine whether the active treatment provides greater improvement in melasma severity and quality of life.
Participants will:
Be randomly assigned to receive either the active topical formulation or a placebo cream.
Apply the assigned treatment daily for 4 weeks. Attend scheduled clinical visits for assessment of melasma severity using the Melasma Area and Severity Index (MASI), quality of life using the Melasma Quality of Life Scale (MelasQoL), and standardized facial imaging with the VISIA® skin analysis system.
Be monitored for local adverse events throughout the study.
Inclusion Criteria:
Exclusion Criteria:
The investigational product and placebo were prepared, coded, and labeled by personnel independent of the clinical investigators. Participants, investigators, and outcome assessors remained blinded to treatment allocation throughout the study. The treatment code was maintained separately and was not disclosed until completion of the study.
Participants received a topical formulation containing 12% azelaic acid and 5% tranexamic acid. The formulation was applied according to the study protocol for 4 weeks.
Participants received a placebo topical formulation identical in appearance and packaging to the investigational product. The placebo was applied according to the study protocol for 4 weeks.
Tijuana, Estado de Baja California 22010, Mexico
Oral and Topical Tranexamic Acid for the Treatment of Melasma
Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma
Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma
Microneedling-Assisted Metformin, Tranexamic Acid, and Modified Kligman's Formula for Melasma
Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma
Randomized Study Using SM-030 Gel for Adults With Melasma
Clinical Efficacy and Mechanisms of a Topical Azone-Tranexamic Acid-Aloe Polysaccharide Gel in the Treatment of Melasma
A Clinical Observation of 1064-nm Q-Switched Fractional Laser Combined With Oral Tranexamic Acid on Treating of Melasma.